anmelden
OMX Copenhagen 20
1.544,40
PKT
+5,93
PKT
+0,39
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu OMX Copenhagen 20-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 29.04.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 22.04.20 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 21.04.20 | A.P. Moeller - Maersk A-S (B) Neutral | Goldman Sachs Group Inc. | |
| 17.04.20 | Novo Nordisk buy | UBS AG | |
| 17.04.20 | A.P. Moeller - Maersk A-S (B) Hold | Deutsche Bank AG | |
| 15.04.20 | A.P. Moeller - Maersk A-S (B) kaufen | Credit Suisse Group | |
| 15.04.20 | Novo Nordisk buy | UBS AG | |
| 15.04.20 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 15.04.20 | Novo Nordisk Outperform | Bernstein Research | |
| 14.04.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 09.04.20 | Novo Nordisk overweight | Barclays Capital | |
| 07.04.20 | Novo Nordisk Hold | Deutsche Bank AG | |
| 07.04.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 06.04.20 | Novo Nordisk Hold | Deutsche Bank AG | |
| 31.03.20 | Novo Nordisk Neutral | Oddo BHF | |
| 27.03.20 | A.P. Moeller - Maersk A-S (B) Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 27.03.20 | A.P. Moeller - Maersk A-S (B) Neutral | JP Morgan Chase & Co. | |
| 24.03.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 23.03.20 | Novo Nordisk buy | UBS AG | |
| 18.03.20 | Novo Nordisk Outperform | Bernstein Research | |
| 17.03.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 17.03.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 17.03.20 | Novo Nordisk overweight | Barclays Capital | |
| 06.03.20 | A.P. Moeller - Maersk A-S (B) kaufen | Jefferies & Company Inc. | |
| 05.03.20 | A.P. Moeller - Maersk A-S (B) Neutral | Goldman Sachs Group Inc. | |
| 02.03.20 | Novo Nordisk overweight | Barclays Capital | |
| 25.02.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 25.02.20 | A.P. Moeller - Maersk A-S (B) verkaufen | JP Morgan Chase & Co. | |
| 21.02.20 | A.P. Moeller - Maersk A-S (B) Hold | Deutsche Bank AG | |
| 20.02.20 | A.P. Moeller - Maersk A-S (B) Neutral | Goldman Sachs Group Inc. | |
| 11.02.20 | Novo Nordisk Hold | Deutsche Bank AG | |
| 06.02.20 | Novo Nordisk Outperform | Credit Suisse Group | |
| 06.02.20 | Novo Nordisk Neutral | UBS AG | |
| 06.02.20 | Novo Nordisk overweight | Barclays Capital | |
| 06.02.20 | Novo Nordisk Outperform | Bernstein Research | |
| 06.02.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 06.02.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 06.02.20 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 05.02.20 | Novo Nordisk overweight | Barclays Capital | |
| 05.02.20 | Novo Nordisk Outperform | Bernstein Research |